Compare LFTO & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFTO | IRON |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.1B |
| IPO Year | 2026 | 2020 |
| Metric | LFTO | IRON |
|---|---|---|
| Price | $15.31 | $62.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 13 |
| Target Price | $33.40 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 706.8K | 559.1K |
| Earning Date | 11-17-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.05 | N/A |
| Revenue Next Year | $15.50 | N/A |
| P/E Ratio | $59.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.02 | $40.00 |
| 52 Week High | $27.94 | $99.50 |
| Indicator | LFTO | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 36.10 | 30.86 |
| Support Level | N/A | $58.30 |
| Resistance Level | $26.23 | $82.89 |
| Average True Range (ATR) | 0.65 | 2.51 |
| MACD | 0.12 | -0.14 |
| Stochastic Oscillator | 9.50 | 34.05 |
Liftoff Mobile Inc is a growth and monetization engine built for the mobile app economy. Its AI-powered platform, Cortex, unifies marketing, creative, and monetization to deliver measurable performance at scale across the app lifecycle. Liftoff enables advertisers to unlock profitable user growth while helping app publishers maximize revenue with ad monetization technology. It delivers tools for user acquisition, engagement, and analytics for mobile apps, along with solutions for agencies and marketers to scale brand and performance campaigns. Additional offerings include access to audiences through SDK-direct publishers and premium ad placements, game intelligence tools through GameRefinery, and resources for building and scaling performance-driven ad creative.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.